Proteome Sciences plc (LON:PRM – Get Free Report)’s share price was up 45.5% on Wednesday . The company traded as high as GBX 2.50 and last traded at GBX 2.40. Approximately 1,057,249 shares were traded during mid-day trading, an increase of 338% from the average daily volume of 241,283 shares. The stock had previously closed at GBX 1.65.
Proteome Sciences Trading Up 11.6%
The company has a debt-to-equity ratio of -258.66, a current ratio of 0.20 and a quick ratio of 0.37. The business’s 50-day moving average is GBX 1.87 and its two-hundred day moving average is GBX 2.68. The firm has a market cap of £7.38 million, a P/E ratio of -2.21 and a beta of 0.07.
Proteome Sciences (LON:PRM – Get Free Report) last posted its quarterly earnings data on Thursday, September 25th. The company reported GBX (0.73) EPS for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.
About Proteome Sciences
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.
See Also
- Five stocks we like better than Proteome Sciences
- Most active stocks: Dollar volume vs share volume
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- What is a SEC Filing?
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Stocks You’ll Wish You Bought Before 2026
Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
